AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026 May 14, 2026 Preclinical AVB-406 data presented in three oral presentations demonstrate the power of the vMiXTM RNAi platform and support planned clinical initiation for Alzheimer’s disease by the end of 2026 Preclinical data show AVB-406 achieved up to 80% MAPT/tau knockdown in the brain
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference May 12, 2026 Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. The live webcast can be [...]
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 2026 May 11, 2026 The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results May 7, 2026 Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026
TACTICA AI Introduces Region’s First AI Platform for Mission-Critical, Real-Time Operational Decisions May 6, 2026 Built on deep tech developed by TII, TACTICA AI moves beyond dashboards to help decision-makers turn fragmented intelligence, sensor, and operational data into action Showcased during Make it in the Emirates 2026, the platform has already been validated through real-world deployments in mission-critical environments Built in Abu Dhabi, connected globally, TACTICA AI integrates partnerships with French-based Safran and Polish-based Satim
D-Wave Announces Qubits Europe 2026 Quantum Computing User Conference May 5, 2026 Event will bring together leading quantum innovators, customers and experts to explore how quantum computing is delivering real-world impact Company to share latest technology roadmap and progress with annealing and gate-model quantum computing, hybrid-quantum software and quantum artificial intelligence (AI)
Aera Technology Introduces Agentic Reasoning for Enterprise Decisions, Moving from Situation to Action in One Conversation May 4, 2026 New capabilities deliver unified decision intelligence across the enterprise, accelerating real-time exploration, reasoning, and execution within a governed platform
OptionMetrics Exhibiting at Commodity Trading Week Europe, May 6-7 May 4, 2026 Experts in historical options data meeting on informative nature of futures options in assessing trading strategies and risk in volatile, fast-moving commodity markets
Brivo Announces UK Expansion, Showcases AI-First Unified Security at The Security Event April 24, 2026 In its post-merger UK debut, Brivo highlights AI-powered products, integrations, and its new London regional office to serve the UK enterprise market